Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 3
1977 10
1978 4
1979 9
1980 9
1981 7
1982 6
1983 8
1984 13
1985 14
1986 17
1987 8
1988 3
1989 6
1990 8
1991 6
1992 3
1993 4
1994 2
1995 11
1996 5
1997 9
1998 1
1999 6
2000 3
2001 5
2002 6
2003 2
2004 3
2005 4
2006 6
2007 5
2008 5
2009 3
2010 4
2011 4
2012 6
2013 2
2014 1
2016 2
2017 1
2018 3
2020 1
2021 1
2022 2
2023 2
2024 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

236 results

Results by year

Filters applied: . Clear all
Page 1
Combination of Sulindac and Eflornithine Delays the Need for Lower Gastrointestinal Surgery in Patients With Familial Adenomatous Polyposis: Post Hoc Analysis of a Randomized Clinical Trial.
Balaguer F, Stoffel EM, Burke CA, Dekker E, Samadder NJ, Van Cutsem E, Lynch PM, Wise PE, Hüneburg R, Lim RM, Boytim ML, Du W, Bruckheimer EM, Cohen A, Church J; FAP-310 Investigators. Balaguer F, et al. Dis Colon Rectum. 2022 Apr 1;65(4):536-545. doi: 10.1097/DCR.0000000000002095. Dis Colon Rectum. 2022. PMID: 34261858 Clinical Trial.
Disease progression was observed in 2 of 54 (3.7%), 9 of 53 (17.0%), and 10 of 51 (19.6%) patients with at least partial lower GI tract in the combination, sulindac, and eflornithine arms, corresponding to risk reductions of 80% (p = 0.02) and 83% (p = 0.01) between combin …
Disease progression was observed in 2 of 54 (3.7%), 9 of 53 (17.0%), and 10 of 51 (19.6%) patients with at least partial lower GI tract in t …
Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention.
Gerner EW, Meyskens FL Jr, Goldschmid S, Lance P, Pelot D. Gerner EW, et al. Amino Acids. 2007 Aug;33(2):189-95. doi: 10.1007/s00726-007-0515-2. Epub 2007 Mar 30. Amino Acids. 2007. PMID: 17396214 Free article. Review.
A Phase IIb clinical study comparing the combination of DFMO and the NSAID sulindac versus placebo was conducted. Endpoints were colorectal tissue polyamine and prostaglandin E2 contents and overall toxicity to participants. Participants in the Phase IIb study served as a …
A Phase IIb clinical study comparing the combination of DFMO and the NSAID sulindac versus placebo was conducted. Endpoints were colo …
Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.
Samadder NJ, Neklason DW, Boucher KM, Byrne KR, Kanth P, Samowitz W, Jones D, Tavtigian SV, Done MW, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Davis R, Topham MK, Lynch P, Strait E, McKinnon W, Burt RW, Kuwada SK. Samadder NJ, et al. JAMA. 2016 Mar 22-29;315(12):1266-75. doi: 10.1001/jama.2016.2522. JAMA. 2016. PMID: 27002448 Free PMC article. Clinical Trial.
INTERVENTIONS: Participants with FAP were randomized to sulindac (150 mg) twice daily and erlotinib (75 mg) daily (n = 46) vs placebo (n = 46) for 6 months. ...CONCLUSIONS AND RELEVANCE: Among participants with FAP, the use of sulindac and erlotinib compared with pl …
INTERVENTIONS: Participants with FAP were randomized to sulindac (150 mg) twice daily and erlotinib (75 mg) daily (n = 46) vs placebo …
Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
Samadder NJ, Kuwada SK, Boucher KM, Byrne K, Kanth P, Samowitz W, Jones D, Tavtigian SV, Westover M, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Burt RW, Neklason DW. Samadder NJ, et al. JAMA Oncol. 2018 May 1;4(5):671-677. doi: 10.1001/jamaoncol.2017.5431. JAMA Oncol. 2018. PMID: 29423501 Free PMC article. Clinical Trial.
IMPORTANCE: Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for colorectal polyps and cancer. A combination of sulindac and erlotinib led to a 71% reduction in duodenal polyp burden in a phase 2 trial. ...INTERVENTIONS: Patients were rando …
IMPORTANCE: Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for colorectal polyps and cancer. A combinatio …
Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis.
Burke CA, Dekker E, Lynch P, Samadder NJ, Balaguer F, Hüneburg R, Burn J, Castells A, Gallinger S, Lim R, Stoffel EM, Gupta S, Henderson A, Kallenberg FG, Kanth P, Roos VH, Ginsberg GG, Sinicrope FA, Strassburg CP, Van Cutsem E, Church J, Lalloo F, Willingham FF, Wise PE, Grady WM, Ford M, Weiss JM, Gryfe R, Rustgi AK, Syngal S, Cohen A. Burke CA, et al. N Engl J Med. 2020 Sep 10;383(11):1028-1039. doi: 10.1056/NEJMoa1916063. N Engl J Med. 2020. PMID: 32905675 Clinical Trial.
METHODS: We evaluated the efficacy and safety of the combination of eflornithine and sulindac, as compared with either drug alone, in adults with familial adenomatous polyposis. ...Disease progression occurred in 18 of 56 patients (32%) in the eflornithine-sulindac …
METHODS: We evaluated the efficacy and safety of the combination of eflornithine and sulindac, as compared with either drug alone, in …
Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.
Limburg PJ, Mahoney MR, Ziegler KL, Sontag SJ, Schoen RE, Benya R, Lawson MJ, Weinberg DS, Stoffel E, Chiorean M, Heigh R, Levine J, Della'Zanna G, Rodriguez L, Richmond E, Gostout C, Mandrekar SJ, Smyrk TC; Cancer Prevention Network. Limburg PJ, et al. Cancer Prev Res (Phila). 2011 Feb;4(2):259-69. doi: 10.1158/1940-6207.CAPR-10-0215. Epub 2011 Jan 5. Cancer Prev Res (Phila). 2011. PMID: 21209397 Free PMC article. Clinical Trial.
Sulindac, atorvastatin, or prebiotic dietary fiber may reduce colorectal cancer (CRC) risk. ...Intervention assignments were as follows: (a) atorvastatin 20 mg qd; (b) sulindac 150 mg bid; (c) oligofructose-enriched inulin (as ORAFTI Synergy1) 6 gm bid; or (d) contr …
Sulindac, atorvastatin, or prebiotic dietary fiber may reduce colorectal cancer (CRC) risk. ...Intervention assignments were as follo …
Sulindac.
Green D, Ts'ao CH, Rossi EC. Green D, et al. Lancet. 1977 Apr 9;1(8015):804. doi: 10.1016/s0140-6736(77)92991-9. Lancet. 1977. PMID: 66601 Clinical Trial. No abstract available.
Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.
McLaren CE, Fujikawa-Brooks S, Chen WP, Gillen DL, Pelot D, Gerner EW, Meyskens FL Jr. McLaren CE, et al. Cancer Prev Res (Phila). 2008 Dec;1(7):514-21. doi: 10.1158/1940-6207.CAPR-08-0074. Cancer Prev Res (Phila). 2008. PMID: 19139001 Free PMC article. Clinical Trial.
There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group. ...There is a <2 dB difference in mean threshold for patients treated with DFMO plus …
There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically signific …
236 results